Close Menu

NEW YORK – JP Morgan said today that it has downgraded the stock of both Luminex and Accelerate Diagnostics to Underweight from Neutral.

The investment bank adjusted its December 2020 price target for Luminex's stock to $21 from $23.00, and kept its December 2020 price target for Accelerate Diagnostics' stock at $16.00.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.